Short Versus Long Protocol for IVF and IVF+ICSI

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to

1. frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure)

2. quality of life (2. outcome measure)

3. live birth rate (2. outcome measure)

4. gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol and vascular endothelial growth factor in follicular fluid(not only compared between GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS and patients becoming pregnant and not becoming pregnant (2. outcome measure), and

5. number of oocytes removed per treatment, number of embryo transfers per treatment and number of spontaneous abortions per treatment (these three parameters are tertiary outcome measures).

In addition to the above mentioned efficacy outcome measures the safety outcome measure "frequency of known side-effects" will be compared between the two protocols.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peter Hornnes, MD, DMSc
• Treatments: Deslorelin

Criteria

Inclusion Criteria:

• All patients referred for infertility receiving their first IVF or IVF+ICSI treatment

Exclusion Criteria:

• Previous IVF or IVF+ICSI-treatment

• Uterine anomalies

• It is necessary to perform direct sperm aspiration from husband's/partner's testicles

• Allergy to one of the intervention products

• Patient is 40 years or above